<code id='7DA3AB99A4'></code><style id='7DA3AB99A4'></style>
    • <acronym id='7DA3AB99A4'></acronym>
      <center id='7DA3AB99A4'><center id='7DA3AB99A4'><tfoot id='7DA3AB99A4'></tfoot></center><abbr id='7DA3AB99A4'><dir id='7DA3AB99A4'><tfoot id='7DA3AB99A4'></tfoot><noframes id='7DA3AB99A4'>

    • <optgroup id='7DA3AB99A4'><strike id='7DA3AB99A4'><sup id='7DA3AB99A4'></sup></strike><code id='7DA3AB99A4'></code></optgroup>
        1. <b id='7DA3AB99A4'><label id='7DA3AB99A4'><select id='7DA3AB99A4'><dt id='7DA3AB99A4'><span id='7DA3AB99A4'></span></dt></select></label></b><u id='7DA3AB99A4'></u>
          <i id='7DA3AB99A4'><strike id='7DA3AB99A4'><tt id='7DA3AB99A4'><pre id='7DA3AB99A4'></pre></tt></strike></i>

          leisure time

          leisure time

          author:Wikipedia    Page View:29844
          UnitedHealth Group
          UnitedHealth Group’s Optum will pay $3.3 billion total for the home health giant Amedisys. Jim Mone/AP

          Home health and hospice chain Amedisys has chosen a new corporate owner.

          Amedisys and UnitedHealth Group’s Optum agreed to a deal Monday in which UnitedHealth will pay $101 per share in cash for Amedisys, totaling $3.3 billion. UnitedHealth’s latest offer is $1 per share higher than what it proposed in its unsolicited buyout offer a few weeks ago.

          advertisement

          Option Care Health, a company that delivers intravenous medicines and mails health care supplies to people’s homes, originally offered to acquire Amedisys in May in an all-stock deal. However, the attractiveness of that deal deteriorated after Option Care’s stock price plummeted soon after the company made its bid.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          knowledge

          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more
          What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise
          What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

          MollyFerguson/STATHello!SometakesandthoughtsonGilead’sTrodelvytroubles,ElevationOncology’ssurprising

          read more
          Hepatitis C has a cure — but many Americans still lack access to it
          Hepatitis C has a cure — but many Americans still lack access to it

          AdobeIn2005,NickVoyleswasdiagnosedwithhepatitisCafterbeingreleasedfromfiveyearsofincarceration.Anurs

          read more

          Test for long Covid? Researchers find new clue in blood samples

          AdobeLongCovidhaslongeludedscientistslookingforitscause.Notknowingwhattriggersitspersistentanddistre